Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Terminated 2Recruiting 2Unknown 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Breast Neoplasms 23Breast Carcinoma In Situ 3Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Inflammatory Breast Neoplasms 1Endometrial Neoplasms 1Cardiotoxicity 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Metastatic 1Barrett Esophagus 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Tamoxifen × Clear all
NCT01685255 2019-03-11

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Incyte Corporation

Phase 2 Terminated
83 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

NCT00206492 2017-08-01

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Baylor Breast Care Center

Phase 2 Terminated
3 enrolled
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡